Humedix Co Ltd

Humedix maintains a strong liquidity position, with a current ratio of 8.7 and free cash flow of KRW 43.7 billion, indicating robust short-term financial flexibility. The company’s price-to-book ratio of 1.22 and price-to-tangible-book ratio of 1.22 suggest a market valuation in line with its equity base, while the price-to-earnings ratio of 7.08 reflects a relatively low multiple compared to earnings. Profitability metrics show a return on equity (ROE) of 17.29% and return on assets (ROA) of 16%, both exceeding the typical thresholds for the pharmaceutical industry, which often prioritizes ROE above 10% and ROA above 8%. The company’s operating margin of 25.5% (calculated from operating income of KRW 43.4 billion on revenue of KRW 170.1 billion) is also well above the median for its industry. Geographically, Humedix operates primarily in the domestic Korean market, with limited exposure to overseas markets as disclosed in its business description. The company does not provide segment-specific revenue breakdowns, but its product portfolio spans pharmaceuticals, APIs, and cosmetics, indicating a diversified revenue base within the healthcare sector. Looking ahead, the company is projected to maintain a stable growth trajectory, with no significant revenue decline or acceleration indicated in the outlook. Analysts have assigned a mean price target of KRW 65,000, suggesting a potential upside of 82.4% from the current market price of KRW 35,650. Risk factors remain low, with no immediate liquidity or dilution concerns identified. The company’s debt-to-equity ratio is 0.0, and its long-term debt is minimal at KRW 1.36 billion, indicating a conservative capital structure. No dilution risks are flagged in filings or transcripts, and the company has not issued additional shares recently. Recent events include the publication of analyst price targets and recommendations, with a mean recommendation of 1.33 (strong buy to hold) and two strong-buy ratings. No material regulatory or geopolitical events have been disclosed in the latest filings, and the company’s exposure to geopolitical drivers in the pharmaceutical industry remains low.